Not a slam dunk

When the discovery of megakaryocyte growth and development factor (MGDF) was announced in June 1994, Wall Street immediately assumed that the course of development for the platelet booster, also known as thrombopoietin (TPO), would be a smooth ride. But not all proteins are easy to develop into drugs, and some can't be turned into drugs at all.